2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Zoledronic Acid
4
Denosumab
3
Vitamin D
2
saracatinib
1
radium Ra 223 dichloride
1
odanacatib
1
etelcalcetide hydrochloride
1
cabozantinib
1
Standard of Care
1
Progestins
1
Pamidronate
1
Paclitaxel
1
Hormone Replacement Therapy
1
Exercise
1
Estrogens
1
Estrogen Replacement Therapy
1
Dietary Supplements
1
Diet, Fat-Restricted
1
Calcium
1
Bone Marrow Transplantation
1
BHQ880
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Diseases
×
etelcalcetide hydrochloride
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts